Comprehensive solution for cDPI: opportunities, trends and possibilities
Inhalation delivery has gained wide acceptance as an effective non-invasive method for local and systemic therapeutic delivery of active pharmaceutical ingredients (APIs). This is due to the unique features of the lungs displaying a large surface area, thin alveolar capillary membrane, low enzymatic activity and avoidance of first pass metabolism.
One of the most used platforms in this technology are capsule based dry powder inhalation (cDPI). This webinar explains from a scientific standpoint why they are interesting within the pharmaceutical community.
The webinar will provide a comprehensive overview of the benefits of capsules in DPIs. It will consider various aspects of cDPI and deliver a state of the art review of the technology and solution available from ACG. It will showcase how ACG’s holistic approach to DPIs as a delivery system enables customers to take advantage of our science and engineering capabilities.
Scientific Business Development Manager – ACG Worldwide
Fernando Diez holds a degree in chemistry followed by an MBA. He is responsible for creating new business opportunities outside of the formal review/tender process and collaborate with external researching institutes and R&D centres. Major part of his career was dedciated to pharmaceutical industry and have worked with renowned multi-national companies in past.
Business Development Manager - ACG North America
Justin Kalafat is responsible for collaborating with pharmaceutical industry for capsule business. Prior to joining ACG in 2014, his background includes degrees in chemistry and roles within the generic pharmaceutical industry in quality control and procurement. His experiences enable key strategies to be developed with customers, R&D focused institutions and universities on the technical aspects of capsules as a dosage form solution.